{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T02:58:38Z","timestamp":1649213918068},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T00:00:00Z","timestamp":1428537600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12985-015-0283-7","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T04:51:19Z","timestamp":1428468679000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV\/AIDS in South Korea"],"prefix":"10.1186","volume":"12","author":[{"given":"Oh-Kyung","family":"Kwon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Soon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Eun","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mee-Kyung","family":"Kee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye-Ri","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-yeon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,9]]},"reference":[{"key":"283_CR1","unstructured":"Antiretroviral drugs used in the treatment of HIV infection. US Food and Drug Administration. http:\/\/www.fda.gov\/forpatients\/illness\/hivaids\/treatment\/ucm118915.htm."},{"issue":"9","key":"283_CR2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","volume":"72","author":"MW Tang","year":"2012","unstructured":"Tang MW, Shafer RW. HIV-1 antiretroviral resistance scientific principles and clinical applications. Drugs. 2012;72(9):e1\u201325.","journal-title":"Drugs"},{"issue":"16","key":"283_CR3","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1089\/08892220152644250","volume":"17","author":"H Sung","year":"2001","unstructured":"Sung H, Foley BT, Bae IG, Chi HS, Cho YK. Phylogenetic analysis of reverse transcriptase in antiretroviral drug-na\u00efve Korean HIV type 1 patients. AIDS Res Hum Retroviruses. 2001;17(16):1549\u201354.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"6","key":"283_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1089\/088922203766774586","volume":"19","author":"H Sung","year":"2003","unstructured":"Sung H, Foley BT, Ahn SH, Kim YB, Chae JD, Shin YO, et al. Natural polymorphisms of protease in protease inhibitor-naive HIV-1 infected patients in Korea: a novel L63M in subtype B. AIDS Res Hum Retroviruses. 2003;19(6):525\u201330.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"283_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.antiviral.2009.09.015","volume":"85","author":"R Paredes","year":"2010","unstructured":"Paredes R, Clotet B. Clinical management of HIV-1 resistance. Antiviral Res. 2010;85:245\u201365.","journal-title":"Antiviral Res"},{"issue":"1","key":"283_CR6","first-page":"6","volume":"21","author":"VA Johnson","year":"2013","unstructured":"Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013;21(1):6\u201314.","journal-title":"Top Antivir Med"},{"issue":"1","key":"283_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jac\/dkt316","volume":"69","author":"GL Melikian","year":"2014","unstructured":"Melikian GL, Rhee SY, Varghese V, Porter D, White K, Taylor J, et al. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother. 2014;69(1):12\u201320.","journal-title":"J Antimicrob Chemother"},{"key":"283_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2146\/ajhp080559","volume":"67","author":"RK Elsayed","year":"2010","unstructured":"Elsayed RK, Caldwell DJ. Etravirine: a novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection. Am J Health Syst Pharm. 2010;67:193\u2013205.","journal-title":"Am J Health Syst Pharm"},{"key":"283_CR9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3851\/IMP1651","volume":"15","author":"WJ Towner","year":"2010","unstructured":"Towner WJ, Cassetti I, Domingo P, Nijs S, Kakuda TN, Vingerhoets J, et al. Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. Antivir Ther. 2010;15:803\u201316.","journal-title":"Antivir Ther"},{"key":"283_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s15010-011-0237-y","volume":"40","author":"G Sterrantino","year":"2012","unstructured":"Sterrantino G, Zaccarelli M, Colao G, Baldanti F, Di Giambenedetto S, Carli T, et al. Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis. Infection. 2012;40:311\u20138.","journal-title":"Infection"},{"issue":"6","key":"283_CR11","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1128\/AAC.00096-10","volume":"54","author":"A Talbot","year":"2010","unstructured":"Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, et al. Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Antimicrob Agents Chemother. 2010;54(6):2473\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"283_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","volume":"85","author":"MP de Bethune","year":"2010","unstructured":"de Bethune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20\u00a0years (1989\u20132009). Antiviral Res. 2010;85:75\u201390.","journal-title":"Antiviral Res"},{"key":"283_CR13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1097\/QAD.0b013e328336ac2a","volume":"24","author":"M Peeters","year":"2010","unstructured":"Peeters M, Vingerhoets J, Tambuyzer L, Azijn H, Hill A, De Meyer S, et al. Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials. AIDS. 2010;24:921\u201330.","journal-title":"AIDS"},{"key":"283_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.antiviral.2009.10.003","volume":"85","author":"AM Wensing","year":"2010","unstructured":"Wensing AM, van Maarseveen NM, Nijhuis M. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res. 2010;85:59\u201374.","journal-title":"Antiviral Res"},{"key":"283_CR15","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3851\/IMP1697","volume":"15","author":"I Dierynck","year":"2010","unstructured":"Dierynck I, De Meyer S, Lathouwers E, Vanden Abeele C, Van De Casteele T, Spinosa-Guzman S, et al. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-na\u00efve patients. Antivir Ther. 2010;15:1161\u20139.","journal-title":"Antivir Ther"},{"issue":"16","key":"283_CR16","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1097\/QAD.0b013e32833d89fa","volume":"24","author":"A Barrail-Tran","year":"2010","unstructured":"Barrail-Tran A, Yazdanpanah Y, Goldwirt L, Chene G, Colin C, Piketty C, et al. Pharmacokinetics of etravirine, raltegravir and darunavir\/ritonavir in treatment-experienced patients. AIDS. 2010;24(16):2581\u20133.","journal-title":"AIDS"},{"issue":"23","key":"283_CR17","doi-asserted-by":"publisher","first-page":"12983","DOI":"10.1128\/JVI.02005-12","volume":"86","author":"HT Xu","year":"2012","unstructured":"Xu HT, Oliveira M, Asahchop EL, McCallum M, Quashie PK, Han Y, et al. Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptase. J Virol. 2012;86(23):12983\u201390.","journal-title":"J Virol"},{"issue":"4","key":"283_CR18","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1128\/JVI.78.4.1718-1729.2004","volume":"78","author":"H Zhang","year":"2004","unstructured":"Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, Siliciano J, et al. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol. 2004;78(4):1718\u201329.","journal-title":"J Virol"},{"key":"283_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jcv.2010.09.012","volume":"50","author":"JY Choi","year":"2011","unstructured":"Choi JY, Kwon OK, Choi SY, Park YK, Kim SS. Drug susceptibility of human immunodeficiency virus type 1-derived pseudoviruses from treatment-experienced patients to protease inhibitors and reverse transcriptase inhibitors, using a modified single-round assay. J Clin Virol. 2011;50:19\u201325.","journal-title":"J Clin Virol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-015-0283-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12985-015-0283-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-015-0283-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-015-0283-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T11:11:16Z","timestamp":1630581076000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-015-0283-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,9]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["283"],"URL":"https:\/\/doi.org\/10.1186\/s12985-015-0283-7","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,9]]},"assertion":[{"value":"29 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"53"}}